Chronic Lung and Gastrointestinal Diseases: Take a Broader Perspective
Downloads
Chronic lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are often found with gastrointestinal symptoms or even gastrointestinal diseases as one of its comorbid. Vice versa, many cases of gastrointestinal diseases such as gastroesophageal reflux disease (GERD) have developed respiratory dysfunction later. The connection between these two systems has become interesting lately and has led to several studies to prove the association. Several theories have emerged to explain this association. This includes changes in microbiota, the mucosa-related immune system of both systems, side effects of the therapeutic given, and pathomechanism related to gastrointestinal diseases such as GERD. Many studies try to prove the connection between the microbiota in the respiratory and gastrointestinal system, and changing the abundance in one of the systems can affect another. Both of the systems also have a similar mucosal membrane in their lining. Those membranes have an immune defence called Mucosal-Associated Lymphoid Tissue (MALT). Lymphatic and circulatory systems facilitate the migration between two mucosal, and these interconnections influence each other. Although the side effect of the therapeutic agent in respiratory diseases (such as inhaled corticosteroid, beta-2 agonist, or anti-cholinergic) is thought to be one of the causative mechanisms, discontinuation of therapy is the second option. Probiotic supplementation to improve microbiota is still not a strong recommendation for management.
Chunxi L, Haiyue L, Yanxia L, et al. The Gut Microbiota and Respiratory Diseases: New Evidence. J Immunol Res 2020; 2020: 2340670.
(GINA) GI for A. Global Strategy for Asthma Management and Prevention (2021 Update). Wisconsin, 2021.
Ojha UC, Singh DP, Choudhari OK, et al. Correlation of Severity of Functional Gastrointestinal Disease Symptoms with that of Asthma and Chronic Obstructive Pulmonary Disease: A Multicenter Study. Int J Appl Basic Med Res 2018; 8: 83–88.
Mastronarde JG. Is There a Relationship Between GERD and Asthma? Gastroenterol Hepatol (N Y) 2012; 8: 401–403.
(GOLD) GI for COLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2021 Report). 2021.
Valdes AM, Walter J, Segal E, et al. Role of the gut Microbiota in Nutrition and Health. BMJ 2018; 361: k2179.
Marsland BJ, Trompette A, Gollwitzer ES. The Gut-Lung Axis in Respiratory Disease. Ann Am Thorac Soc 2015; 12 Suppl 2: S150-6.
Kuper C, Wijnands M, Zander S. Mucosa-Associated Lymphoid Tissues. 2017, pp. 81–121.
Vieira WA, Pretorius E. The Impact of Asthma on the Gastrointestinal Tract (GIT). J Asthma Allergy 2010; 3: 123–130.
Heffler E, Madeira LNG, Ferrando M, et al. Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. J Allergy Clin Immunol Pract 2018; 6: 776–781.
Hansen RA, Tu W, Wang J, et al. Risk of Adverse Gastrointestinal Events from Inhaled Corticosteroids. Pharmacotherapy 2008; 28: 1325–1334.
Saag KG, Furst DE, Barnes PJ. Major Side Effects of Inhaled Glucocorticoids. UpToDate, https://www.uptodate.com/contents/major-side-effects-of-inhaled-glucocorticoids#H27 (2018, accessed 6 October 2021).
Katzung BG. Basic and Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education, 2017.
Pandya D, Puttanna A, Balagopal V. Systemic Effects of Inhaled Corticosteroids: An Overview. Open Respir Med J 2014; 8: 59–65.
Drupals M, Ware M. Toronto Notes 2021: Comprehensive Medical Reference and a Review for the Medical Council of Canada Qualifying Exam (MCCQE). Toronto, 2021.
Alwi I, Salim S, Hidayat R, et al. Penatalaksanaan di Bidang Ilmu Penyakit Dalam: Panduan Praktik Klinis. 4th ed. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam, 2019.
Lee AS, Lee JS, He Z, et al. Reflux-Aspiration in Chronic Lung Disease. Ann Am Thorac Soc 2020; 17: 155–164.
Franssen FME, Rochester CL. Comorbidities in Patients with COPD and Pulmonary Rehabilitation: Do They Matter? Eur Respir Rev 2014; 23: 131–141.
Sanchez J, Schumann DM, Karakioulaki M, et al. Laryngopharyngeal Reflux in Chronic Obstructive Pulmonary Disease - A Multi-Centre Study. Respir Res 2020; 21: 220.
Morehead RS. Gastro-Oesophageal Reflux Disease and Non-Asthma Lung Disease. Eur Respir Rev 2009; 18: 233–243.
Meyer KC. Gastroesophageal Reflux and Lung Disease. Expert Rev Respir Med 2015; 9: 383–385.
Cvejic L, Harding R, Churchward T, et al. Laryngeal Penetration and Aspiration in Individuals with Stable COPD. Respirology 2011; 16: 269–275.
Wang Y-T, Tsai M-C, Wang Y-H, et al. Association between Proton Pump Inhibitors and Asthma: A Population-Based Cohort Study. Front Pharmacol 2020; 11: 607.
Trukhmanov AS. Diagnosis and Treatment of Gastroesophageal Reflux Disease. Terapevticheskii Arkhiv 2011; 83: 44–48.
Yudhawati R, Parasetiyo YD. Imunopatogenesis Penyakit Paru Obstruktif Kronik. Jurnal Respirasi. 2018; 4(1): 19-25. [CrossReff]
Puspita F, Putri L, Rahardja C, et al. Prevalence of Gastroesophageal Reflux Disease and Its Risk Factors in Rural Area. Indones J Gastroenterol Hepatol Dig Endosc 2017; 18: 9. [PubMed]
Indonesia PDP. Penyakit Paru Obstruktif Kronik (PPOK): Diagnosis dan Penatalaksanaan. Jakarta: UI Press, 2016.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (